Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

키워드

참고문헌 (7)

1. Tseng TC, "Elimination of hepatitis B : is it a mission possible?", BMC Med, 15, pp.53~ (2017)
2. Lilian Yan Liang, "Unmet need in chronic hepatitis B management", Clinical and Molecular Hepatology, 25(2), pp.172~180 (2019), 대한간학회
3. Hagins D, "Switching to coformulated rilpivirine(RPV), emtricitabine(FTC)and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate(TDF)or efavirenz, FTC and TDF : 96-week results from two randomized clinical trials", HIV Med, 19, pp.724~733 (2018)
4. Kauppinen KJ, "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting", AIDS Patient Care STDS, 33, pp.500~506 (2019)
5. Joonho Jeong, "Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis", Clinical and Molecular Hepatology, 28(2), pp.254~264 (2022), 대한간학회[DOI]
6. Shaheen AA, "Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers", Aliment Pharmacol Ther, 46, pp.599~604 (2017)
7. Taramasso L, "Lipid profile changings after switching from rilpivirine", tenofovir disoproxil fumarate, tenofovir alafenamide, pp.emtricitabine : different effects in patients with or without baseline hypercholesterolemia, PLoS One[DOI]

관련 논문AI추천